It also preserves the Rett voucher; and prior EMA approval plus Rett approval ought to boost the chances for FDA approving blarcamesine for Alzheimer's.
I think EMA is the smarter route too. Better with a first approval
There is still a very good chance the FDA will beat the EMA to approval. I don't believe for a second that AVXL is sitting on their hands with the FDA.
The FDA is on notice though, and therein is the benefit of initiation of the EMA's regulatory submission announcement, on a timeline.